Genome Medical, a South San Francisco, CA-based telegenomics technology and services company democratizing access to genomic-based medicine, raised $14m in Series B extension funding.
This round, which brought the total capital raised since 2016 to $60m, was led by Samsung Catalyst Fund, with participation from Chairman and Co-founder Randy Scott, Canaan Partners, Illumina Ventures, Echo Health Ventures, Perceptive Advisors, LRVHealth, Kaiser Permanente Ventures, Avestria Ventures, Casdin Capital, HealthInvest Equity Partners, Revelation Partners, Dreamers Fund, Flywheel Ventures and Manatt Ventures.
The company intends to use the funds to accelerated development of the Genome Care DeliveryTM technology platform for cancer, reproductive health and pharmacogenomics.
Led by Lisa Alderson, CEO and Co-founder, Genome Medical Genome Medical is a national telegenomics technology, services and strategy company bringing genomic medicine to everyday care. Through a nationwide network of genetic specialists and efficient Genome Care Delivery technology platform, the company provides expert virtual genetic care for individuals and their families to improve health and well-being. It also helps health care providers and their patients navigate the field of genetics and utilize test results to understand the risk for disease, accelerate disease diagnosis, make informed treatment decisions and lower the cost of care.
Genome Medical’s solutions are utilized by health systems, hospitals, payors, providers and employers to expand access to genetic health services. The company also services patients directly and accepts self-referrals.